Medicare Enrolled

Dr. Lee Greenspon, M.D.

Pulmonary Disease · Wynnewood, PA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
100 E LANCASTER AVE, Wynnewood, PA 19096
6106423796
In practice since 2006 (20 years)
NPI: 1164467122 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Greenspon from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Greenspon? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Greenspon

Dr. Lee Greenspon is a pulmonary disease specialist in Wynnewood, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Greenspon performed 1,287 Medicare services across 907 unique beneficiaries.

Between the years covered by Open Payments, Dr. Greenspon received a total of $6,191 from 41 pharmaceutical and/or device companies across 311 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Greenspon is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 19% volume in PA $6,191 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,287
Medicare services
Top 19% in PA for pulmonary disease
907
Unique beneficiaries
$72
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~64 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Expiratory airflow and volume test
A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume.
495 $22 $80
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
371 $103 $170
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
87 $146 $240
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
63 $66 $95
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
44 $100 $144
New patient office visit, complex (60-74 min) 42 $177 $325
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
41 $69 $120
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
40 $134 $240
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
34 $145 $270
Lung cancer screening counseling visit
A visit to discuss the need for lung cancer screening using a low-dose CT scan. This service is used to determine eligibility and facilitate shared decision making.
25 $29 $45
Smoking cessation counseling, 4-10 minutes
A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation.
17 $15 $20
Pulmonary gas exchange test
A test to examine how well the lungs exchange gases.
15 $6 $35
Lung volume test using sensors
A test that measures the amount of air in the lungs using sensors.
13 $8 $35
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$6,191
Total received (2018-2024)
Avg $884/year across 7 years
Top 26% in PA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
41
Companies
311
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,191 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$809
2023
$1,003
2022
$1,458
2021
$722
2020
$302
2019
$999
2018
$898

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$203
AstraZeneca Pharmaceuticals LP
$152
AngioDynamics, Inc.
$83
Insmed, Inc.
$70
ABBVIE INC.
$51
GENZYME CORPORATION
$49
Electromed, Inc.
$45
Boehringer Ingelheim Pharmaceuticals, Inc.
$32
Genentech USA, Inc.
$24
Novartis Pharmaceuticals Corporation
$24
Alexion Pharmaceuticals, Inc.
$24
Mylan Specialty L.P.
$21
Takeda Pharmaceuticals U.S.A., Inc.
$16
Philips North America LLC
$15
Top 3 companies account for 54.1% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,474
GlaxoSmithKline, LLC.
$1,047
Boehringer Ingelheim Pharmaceuticals, Inc.
$809
GENZYME CORPORATION
$382
Genentech USA, Inc.
$330
Mylan Specialty L.P.
$328
Insmed, Inc.
$264
Philips Electronics North America Corporation
$142
Takeda Pharmaceuticals U.S.A., Inc.
$120
Actelion Pharmaceuticals US, Inc.
$108
ABBVIE INC.
$95
AngioDynamics, Inc.
$83
Regeneron Healthcare Solutions, Inc.
$79
E.R. Squibb & Sons, L.L.C.
$78
Bayer HealthCare Pharmaceuticals Inc.
$65
Novartis Pharmaceuticals Corporation
$64
Exeltis, USA Inc.
$60
ANI Pharmaceuticals, Inc.
$53
Mallinckrodt Hospital Products Inc.
$52
Pulmonx Corporation
$49
United Therapeutics Corporation
$47
Circassia Pharmaceuticals Inc
$46
Electromed, Inc.
$45
Baxter Healthcare
$43
Amgen Inc.
$37
Grifols USA, LLC
$27
Covis Pharma GmBH
$24
Alexion Pharmaceuticals, Inc.
$24
JAZZ PHARMACEUTICALS INC.
$23
Kaleo, Inc.
$20
Teva Pharmaceuticals USA, Inc.
$18
Sunovion Pharmaceuticals Inc.
$18
Celgene Corporation
$17
Allergan Inc.
$17
Resmed Corp
$16
Philips North America LLC
$15
Lilly USA, LLC
$15
Merck Sharp & Dohme LLC
$15
Phadia US Inc.
$15
EKOS Corporation
$15
Merck Sharp & Dohme Corporation
$13
Top 3 companies account for 53.8% of all-time payments
Associated products mentioned in payments ›
(2928) NIV other · (8874) inCourage · (AK6) Vest Therapy · ACTHAR · AIRSUPRA · ALIMTA · ALPHAVAC · ALVESCO · ANORO · ANORO ELLIPTA · ARALAST · ASMANEX · AUVI-Q · AVYCAZ · Abraxane · Adempas · Arikayce · Astral · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · CINQAIR · DUAKLIR PRESSAIR · DUPIXENT · Dymista · EKOSONIC · ELIQUIS · Esbriet · FASENRA · GLASSIA · ImmunoCAP · NIOX VERO · NUCALA · OFEV · OPDIVO · OPSUMIT · OPSUMIT MACITENTAN · PURIFIED CORTROPHIN GEL · Perforomist · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · ULTOMIRIS · UPTRAVI · Utibron · Wellcentive Undiv · XOLAIR · XYREM · Xolair · YUPELRI · Yupelri · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a pulmonary disease specialist in Wynnewood?
Compare pulmonary diseases in the Wynnewood area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases within 10 mi
264
Per 100K population
30.7
County median income
$111,521
Nearest hospital
MAIN LINE HOSPITAL LANKENAU
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Greenspon is a clinical cardiology specialist, with above-average Medicare volume (top 19% in PA), with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Greenspon experienced with expiratory airflow and volume test?
Based on Medicare claims data, Dr. Greenspon performed 495 expiratory airflow and volume test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Greenspon receive payments from pharmaceutical companies?
Yes. Dr. Greenspon received a total of $6,191 from 41 companies across 311 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Greenspon's costs compare to other pulmonary diseases in Wynnewood?
Dr. Greenspon's average Medicare payment per service is $72. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Greenspon) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →